The key end point was the safety and tolerability of sifalimumab. Treatment method-emergent adverse situations (AEs) and serious AEs (SAEs) as well as their severity, consequence, and any partnership for the examine medication had been recorded with the investigator through the analyze. AEs have been regarded prone to be related https://indiraf544seo7.wikinarration.com/user